<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29066436</article-id><article-id pub-id-type="pmc">5721825</article-id><article-id pub-id-type="doi">10.1161/JAHA.117.005637</article-id><article-id pub-id-type="publisher-id">JAH32535</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Interleukin&#x02010;6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID&#x02010;TIMI 52 (Stabilization of Plaque Using Darapladib&#x02014;Thrombolysis in Myocardial Infarction 52) Trial</article-title><alt-title alt-title-type="left-running-head">Fanola et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32535-cr-0001" contrib-type="author" corresp="yes"><name><surname>Fanola</surname><given-names>Christina L.</given-names></name><degrees>MD, MSc</degrees><address><email>clfanola@gmail.com</email></address><xref ref-type="aff" rid="jah32535-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32535-cr-0002" contrib-type="author"><name><surname>Morrow</surname><given-names>David A.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="jah32535-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32535-cr-0003" contrib-type="author"><name><surname>Cannon</surname><given-names>Christopher P.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32535-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32535-cr-0004" contrib-type="author"><name><surname>Jarolim</surname><given-names>Petr</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32535-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32535-cr-0005" contrib-type="author"><name><surname>Lukas</surname><given-names>Mary Ann</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32535-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32535-cr-0006" contrib-type="author"><name><surname>Bode</surname><given-names>Christoph</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32535-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32535-cr-0007" contrib-type="author"><name><surname>Hochman</surname><given-names>Judith S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32535-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32535-cr-0008" contrib-type="author"><name><surname>Goodrich</surname><given-names>Erica L.</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="jah32535-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32535-cr-0009" contrib-type="author"><name><surname>Braunwald</surname><given-names>Eugene</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32535-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32535-cr-0010" contrib-type="author"><name><surname>O'Donoghue</surname><given-names>Michelle L.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="jah32535-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah32535-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">TIMI Study Group</named-content>
<named-content content-type="organisation-division">Division of Cardiovascular Medicine</named-content>
<institution>Brigham and Women's Hospital and Harvard Medical School</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><aff id="jah32535-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Brigham and Women's Hospital and Harvard Medical School</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
</aff><aff id="jah32535-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Metabolic Pathways and Cardiovascular Therapeutic Area</named-content>
<institution>GlaxoSmithKline</institution>
<named-content content-type="city">Philadelphia</named-content>
<named-content content-type="country-part">PA</named-content>
</aff><aff id="jah32535-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Cardiology and Angiology I</named-content>
<institution>University Heart Center Freiburg</institution>
<named-content content-type="city">Freiburg</named-content>
<country country="DE">Germany</country>
</aff><aff id="jah32535-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Division of Cardiology</named-content>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>New York University School of Medicine</institution>
<named-content content-type="city">New York</named-content>
<named-content content-type="country-part">NY</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Christina L. Fanola, MD, MSc, TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, 60 Fenwood Rd, 7th Floor Suite 7022, Boston, MA 02115. E&#x02010;mail: <email>clfanola@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2017</year></pub-date><volume>6</volume><issue>10</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-10</issue-id><elocation-id>e005637</elocation-id><history><date date-type="received"><day>19</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e005637.pdf"/><abstract id="jah32535-abs-0001"><sec id="jah32535-sec-0001"><title>Background</title><p>Interleukin&#x02010;6 (<styled-content style="fixed-case">IL</styled-content>&#x02010;6) is an inflammatory cytokine implicated in plaque instability in acute coronary syndrome (<styled-content style="fixed-case">ACS</styled-content>). We aimed to evaluate the prognostic implications of <styled-content style="fixed-case">IL</styled-content>&#x02010;6 post&#x02010;<styled-content style="fixed-case">ACS</styled-content>.</p></sec><sec id="jah32535-sec-0002"><title>Methods and Results</title><p>
<styled-content style="fixed-case">IL</styled-content>&#x02010;6 concentration was assessed at baseline in 4939 subjects in <styled-content style="fixed-case">SOLID</styled-content>&#x02010;<styled-content style="fixed-case">TIMI</styled-content> 52 (Stabilization of Plaque Using Darapladib&#x02014;Thrombolysis in Myocardial Infarction 52), a randomized trial of darapladib in patients &#x02264;30&#x000a0;days from <styled-content style="fixed-case">ACS</styled-content>. Patients were followed for a median of 2.5&#x000a0;years for major adverse cardiovascular events; cardiovascular death, myocardial infarction, or stroke) and cardiovascular death or heart failure hospitalization. Primary analyses were adjusted first for baseline characteristics, days from index <styled-content style="fixed-case">ACS</styled-content>,<styled-content style="fixed-case"> ACS</styled-content> type, and randomized treatment arm. For every <styled-content style="fixed-case">SD</styled-content> increase in <styled-content style="fixed-case">IL</styled-content>&#x02010;6, there was a 10% higher risk of major adverse cardiovascular events (adjusted hazard ratio [adj <styled-content style="fixed-case">HR</styled-content>] 1.10, 95% confidence interval [<styled-content style="fixed-case">CI</styled-content>] 1.01&#x02010;1.19) and a 22% higher risk of cardiovascular death or heart failure (adj <styled-content style="fixed-case">HR</styled-content> 1.22, 95% <styled-content style="fixed-case">CI</styled-content> 1.11&#x02010;1.34). Patients in the highest <styled-content style="fixed-case">IL</styled-content>&#x02010;6 quartile had a higher risk of major adverse cardiovascular events (adj <styled-content style="fixed-case">HR</styled-content> Q4:Q1 1.57, 95% <styled-content style="fixed-case">CI</styled-content> 1.22&#x02010;2.03) and cardiovascular death or heart failure (adj <styled-content style="fixed-case">HR</styled-content> 2.29, 95% <styled-content style="fixed-case">CI</styled-content> 1.6&#x02010;3.29). After further adjustment for biomarkers (high&#x02010;sensitivity C&#x02010;reactive protein, lipoprotein&#x02010;associated phospholipase A<sub>2</sub> activity, high&#x02010;sensitivity troponin I, and B&#x02010;type natriuretic peptide), <styled-content style="fixed-case">IL</styled-content>&#x02010;6 remained significantly associated with the risk of major adverse cardiovascular events (adj <styled-content style="fixed-case">HR</styled-content> Q4:Q1 1.43, 95% <styled-content style="fixed-case">CI</styled-content> 1.09&#x02010;1.88) and cardiovascular death or heart failure (adj <styled-content style="fixed-case">HR</styled-content> 1.79, 95% <styled-content style="fixed-case">CI</styled-content> 1.22&#x02010;2.63).</p></sec><sec id="jah32535-sec-0003"><title>Conclusions</title><p>In patients after <styled-content style="fixed-case">ACS</styled-content>,<styled-content style="fixed-case"> IL</styled-content>&#x02010;6 concentration is associated with adverse cardiovascular outcomes independent of established risk predictors and biomarkers. These findings lend support to the concept of <styled-content style="fixed-case">IL</styled-content>&#x02010;6 as a potential therapeutic target in patients with unstable ischemic heart disease.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32535-kwd-0001">acute coronary syndrome</kwd><kwd id="jah32535-kwd-0002">atherosclerosis</kwd><kwd id="jah32535-kwd-0003">biomarker</kwd><kwd id="jah32535-kwd-0004">inflammation</kwd><kwd id="jah32535-kwd-0005">vascular biology</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Inflammation</kwd><kwd>Biomarkers</kwd><kwd>Coronary Circulation</kwd></kwd-group><funding-group><award-group><funding-source>GlaxoSmithKline</funding-source></award-group><award-group><funding-source>Singulex</funding-source></award-group><award-group><funding-source>Abbott Laboratories</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="10"/><word-count count="6501"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32535</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:24.10.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32535-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005637</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.005637">10.1161/JAHA.117.005637</ext-link>.)<pub-id pub-id-type="pmid">29066436</pub-id></mixed-citation>
</p></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="jah32535-blkfxd-0001" orientation="portrait"><sec id="jah32535-sec-0005"><title>Clinical Perspective</title><sec id="jah32535-sec-0006"><title>What Is New?</title><p>
<list list-type="bullet" id="jah32535-list-0001"><list-item><p>Interleukin&#x02010;6 (IL&#x02010;6) is an inflammatory cytokine implicated in plaque instability in acute coronary syndromes. However, it's prognostic relevance in patients after an acute coronary syndrome has remained unclear.</p></list-item><list-item><p>We determined that IL&#x02010;6 is associated with an increased risk of major adverse cardiovascular events including heart failure.</p></list-item><list-item><p>This relationship was independent of established clinical predictors and risk markers including hsCRP, Lp&#x02010;PLA2 activity, hsTnI, and BNP.</p></list-item></list>
</p></sec><sec id="jah32535-sec-0007"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah32535-list-0002"><list-item><p>The inflammatory cytokine IL&#x02010;6 may be useful for risk stratification in patients after an acute coronary syndrome.</p></list-item><list-item><p>These findings lend support to studies that are investigating a possible role for interleukin&#x02010;6 as a therapeutic target in patients with unstable coronary artery disease.</p></list-item></list>
</p></sec></sec></boxed-text>
</p><sec id="jah32535-sec-0008"><title>Introduction</title><p>Initiation and progression of subclinical atherosclerosis to plaque instability and rupture in acute coronary syndrome (ACS) comprise a complex process driven by both vascular lipoprotein accumulation and inflammation.<xref rid="jah32535-bib-0001" ref-type="ref">1</xref> Interleukin&#x02010;6 (IL&#x02010;6) is a cytokine that has been implicated in vascular inflammation<xref rid="jah32535-bib-0002" ref-type="ref">2</xref> and the initiation and progression of atherosclerosis and degradation of the fibrous cap contributing to plaque instability.<xref rid="jah32535-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32535-bib-0004" ref-type="ref">4</xref> IL&#x02010;6 propagates inflammation and promotes hepatic hs&#x02010;CRP (high&#x02010;sensitivity C&#x02010;reactive protein) production. Prior studies have demonstrated that higher concentrations of IL&#x02010;6 are associated with worse vascular health in individuals without clinical atherosclerosis and are associated with the risk of future myocardial infarction (MI).<xref rid="jah32535-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32535-bib-0006" ref-type="ref">6</xref> In patients with ST&#x02010;elevation MI (STEMI), IL&#x02010;6 has been shown to be upregulated at the site of coronary occlusion.<xref rid="jah32535-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32535-bib-0008" ref-type="ref">8</xref> It has also been suggested that IL&#x02010;6 concentration may be useful for identifying those patients with unstable coronary disease who may benefit more from an invasive strategy.<xref rid="jah32535-bib-0009" ref-type="ref">9</xref>
</p><p>Interest in IL&#x02010;6 as a potential therapeutic target is supported by Mendelian randomization studies that have shown signaling through the IL&#x02010;6 receptor to be directly implicated in the development of coronary heart disease.<xref rid="jah32535-bib-0010" ref-type="ref">10</xref> Moreover, blockade of the IL&#x02010;6 receptor with tocilizumab has been shown to attenuate inflammation and blunt the periprocedural rise in troponin in patients with non&#x02010;ST&#x02010;elevation MI.<xref rid="jah32535-bib-0011" ref-type="ref">11</xref> However, the relationship of IL&#x02010;6 with outcomes in patients after ACS remains incompletely defined. This relationship remains of importance because of interest in the IL&#x02010;1/IL&#x02010;6/CRP axis as a potential therapeutic target.<xref rid="jah32535-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32535-bib-0012" ref-type="ref">12</xref> As an exploratory analysis, we therefore evaluated the association of IL&#x02010;6 with cardiovascular outcomes in a large randomized trial population of an anti&#x02010;inflammatory therapeutic in patients after ACS.</p></sec><sec id="jah32535-sec-0009"><title>Methods and Materials</title><sec id="jah32535-sec-0010"><title>Study Population</title><p>The SOLID&#x02010;TIMI 52 (Stabilization of Plaque Using Darapladib&#x02010;Thrombolysis in Myocardial Infarction 52) study design and trial results have been previously published.<xref rid="jah32535-bib-0013" ref-type="ref">13</xref>, <xref rid="jah32535-bib-0014" ref-type="ref">14</xref> In brief, the trial population enrolled 13&#x000a0;026 moderate&#x02010; to high&#x02010;risk patients across 36 countries within 30&#x000a0;days of hospitalization with an ACS (unstable angina, non&#x02010;ST&#x02010;elevation MI , or STEMI). Patients were randomly allocated to once&#x02010;daily oral darapladib (an inhibitor of the proinflammatory enzyme lipoprotein&#x02010;associated phospholipase A<sub>2</sub>) or matching placebo in a double&#x02010;blinded manner. The use of guideline&#x02010;recommended therapies was strongly encouraged throughout the duration of the trial through the routine distribution of performance reports to sites and country leaders. The median duration of follow&#x02010;up was 2.5&#x000a0;years.</p></sec><sec id="jah32535-sec-0011"><title>Biomarker and Chemistry Assessment</title><p>Serum and plasma samples were collected at baseline in randomly selected patients and stored at &#x02212;20&#x000b0;C or colder for less than 6&#x000a0;weeks and then shipped on dry ice to the TIMI Clinical Trials Laboratory where they were then stored at &#x02212;70&#x000b0;C or colder. Routine blood chemistries and lipoprotein&#x02010;associated phospholipase A<sub>2</sub> activity (diaDexus, Poway, CA) were assessed in all patients at baseline (median 14&#x000a0;days after ACS). Each of the following biomarkers were also assayed in a randomly selected, planned cohort of &#x02248;5000 patients: IL&#x02010;6 (Erenna Immunoassay, Singulex, Inc, Palo Alto, CA), high&#x02010;sensitivity troponin I (hsTnI) and B&#x02010;type natriuretic peptide (BNP, Architect i2000SR; Abbott Laboratories, Abbott Park, IL), and hsCRP (cobas 6000; Roche Diagnostics, Basel, Switzerland).</p></sec><sec id="jah32535-sec-0012"><title>End Point Assessment</title><p>The primary end point for the trial was the composite of coronary heart disease death, MI, or urgent coronary revascularization for myocardial ischemia (major coronary events). Prespecified end points of interest for this analysis included the composite of cardiovascular death, MI, or stroke (major adverse cardiovascular events, MACE), and the composite of cardiovascular death or hospitalization for heart failure (HF). Individual components of the composite end points were also assessed. All events in this analysis were adjudicated by a blinded Clinical Events Committee.</p></sec><sec id="jah32535-sec-0013"><title>Statistical Methods</title><p>Baseline characteristics were examined by IL&#x02010;6 quartiles. Multilevel and single&#x02010;level categorical variables were assessed by &#x003c7;<sup>2</sup> and Cochran Armitage trend tests, respectively, and continuous variables with the Jonckheere&#x02010;Terpstra test. The correlation between IL&#x02010;6 and established biomarkers was evaluated with the Spearman correlation test. Median concentrations of IL&#x02010;6 were compared with the Kruskal&#x02010;Wallis test in those with and without the outcomes of interest. Kaplan&#x02010;Meier rates are reported at 3&#x000a0;years. As a sensitivity analysis, a landmark analysis was performed beyond 30&#x000a0;days in order to assess the long&#x02010;term association of IL&#x02010;6 with recurrent cardiovascular events following the early inflammatory response after ACS.</p><p>The risk of cardiovascular outcomes associated with IL&#x02010;6 quartiles and log&#x02010;transformed IL&#x02010;6 concentration was examined with Cox proportional hazards modeling. The generated hazard ratios (HR) and 95% confidence intervals (CI) were adjusted for age, sex, race (white versus nonwhite), smoking status, diabetes mellitus, body mass index, hypertension, hyperlipidemia, baseline low&#x02010;density lipoprotein levels, prior MI, prior percutaneous coronary intervention, index event (ST&#x02010;elevation ACS or STEMI versus non&#x02010;ST&#x02010;elevation ACS), days from index event, estimated glomerular filtration rate &#x0003c;60&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>, peripheral artery disease, and randomized treatment arm. Of 4939 patients in the biomarker substudy, 4720 (96%) had complete data available for multivariate analysis. The model was subsequently adjusted for established biomarkers, including hsTnI, hsCRP, lipoprotein&#x02010;associated phospholipase A<sub>2</sub> and BNP. A sensitivity analysis was conducted that included left ventricular ejection fraction in the model (available in 84.1% of study population). The interaction between IL&#x02010;6 and the treatment benefit of darapladib was examined by including an interaction term in the models. An additional sensitivity analysis was stratified by index diagnosis (NSTE&#x02010;ACS and STEMI). This was an observational study from a randomized clinical trial cohort. Because this analysis was exploratory, no formal adjustments for multiplicity were performed.</p></sec></sec><sec id="jah32535-sec-0014"><title>Results</title><p>The baseline characteristics of the randomly selected biomarker cohort (n=4939) versus the overall trial population are shown in Table&#x000a0;<xref rid="jah32535-sup-0001" ref-type="supplementary-material">S1</xref>. The median baseline IL&#x02010;6 concentration was 2.02&#x000a0;pg/mL (25th and 75th percentiles 1.16 and 3.97&#x000a0;pg/mL, respectively) when assessed a median of 14&#x000a0;days from the qualifying ACS event. No samples had IL&#x02010;6 values below the lowest detectable level of 0.158&#x000a0;pg/mL.</p><p>In general, higher concentrations of IL&#x02010;6 were associated with female sex, white race, current smoking, diminished renal function (estimated glomerular filtration rate &#x0003c;60&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>), peripheral artery disease, and more diseased coronary vessels at catheterization. Patients with higher concentrations of IL&#x02010;6 were significantly more likely to have STEMI as their index event and to have been enrolled in Western or Eastern Europe. Lower IL&#x02010;6 concentrations were associated with hyperlipidemia and prior MI (Table&#x000a0;<xref rid="jah32535-tbl-0001" ref-type="table-wrap">1</xref>). The use of evidence&#x02010;based therapies was high across groups and the use of statins, aspirin, &#x003b2;&#x02010;blockers, angiotensin&#x02010;converting enzyme inhibitors, or angiotensin II receptor blockers at baseline did not significantly vary across IL&#x02010;6 quartiles. However, patients with higher IL&#x02010;6 concentrations were significantly more likely to undergo percutaneous coronary intervention for the qualifying event and be on a P2Y<sub>12</sub> inhibitor. There were modest to strong correlations between IL&#x02010;6 and hsTnI (<italic>r</italic>=0.48, <italic>P</italic>&#x0003c;0.001) and hsCRP (<italic>r</italic>=0.71, <italic>P</italic>&#x0003c;0.001), and a weaker correlation between IL&#x02010;6 and BNP (<italic>r</italic>=0.24, <italic>P</italic>&#x0003c;0.001).</p><table-wrap id="jah32535-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics Stratified by IL&#x02010;6 Quartile</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Baseline Characteristic</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">N (%)</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Quartile 1 (&#x02264;1.16&#x000a0;pg/mL) N=1236</th><th align="left" valign="top" rowspan="1" colspan="1">Quartile 2 (1.16&#x02010;2.02&#x000a0;pg/mL) N=1236</th><th align="left" valign="top" rowspan="1" colspan="1">Quartile 3 (2.02&#x02010;3.97&#x000a0;pg/mL) N=1233</th><th align="left" valign="top" rowspan="1" colspan="1">Quartile 4 (&#x0003e;3.97&#x000a0;pg/mL) N=1234</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, median (IQR)</td><td align="left" rowspan="1" colspan="1">63 (57, 69)</td><td align="left" rowspan="1" colspan="1">65 (60, 71)</td><td align="left" rowspan="1" colspan="1">64 (59, 71)</td><td align="left" rowspan="1" colspan="1">65 (60, 72)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, median (IQR)</td><td align="left" rowspan="1" colspan="1">26.9 (25.1, 30.1)</td><td align="left" rowspan="1" colspan="1">28.1 (25.1, 31.8)</td><td align="left" rowspan="1" colspan="1">28.2 (25.3, 31.6)</td><td align="left" rowspan="1" colspan="1">27.7 (25.1, 31.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">287 (23.2)</td><td align="left" rowspan="1" colspan="1">324 (26.2)</td><td align="left" rowspan="1" colspan="1">319 (25.9)</td><td align="left" rowspan="1" colspan="1">345 (28.0)</td><td align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">1064 (86.1)</td><td align="left" rowspan="1" colspan="1">1082 (87.5)</td><td align="left" rowspan="1" colspan="1">1103 (89.5)</td><td align="left" rowspan="1" colspan="1">1094 (88.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">28 (2.3)</td><td align="left" rowspan="1" colspan="1">29 (2.3)</td><td align="left" rowspan="1" colspan="1">32 (2.6)</td><td align="left" rowspan="1" colspan="1">37 (3.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">128 (10.4)</td><td align="left" rowspan="1" colspan="1">98 (7.9)</td><td align="left" rowspan="1" colspan="1">84 (6.8)</td><td align="left" rowspan="1" colspan="1">83 (6.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">16 (1.3)</td><td align="left" rowspan="1" colspan="1">27 (2.2)</td><td align="left" rowspan="1" colspan="1">14 (1.1)</td><td align="left" rowspan="1" colspan="1">20 (1.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Region</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">North America</td><td align="left" rowspan="1" colspan="1">352 (28.5)</td><td align="left" rowspan="1" colspan="1">302 (24.4)</td><td align="left" rowspan="1" colspan="1">250 (20.3)</td><td align="left" rowspan="1" colspan="1">215 (17.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">South America</td><td align="left" rowspan="1" colspan="1">91 (7.4)</td><td align="left" rowspan="1" colspan="1">108 (8.7)</td><td align="left" rowspan="1" colspan="1">105 (8.5)</td><td align="left" rowspan="1" colspan="1">88 (7.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Western Europe</td><td align="left" rowspan="1" colspan="1">316 (25.6)</td><td align="left" rowspan="1" colspan="1">339 (27.4)</td><td align="left" rowspan="1" colspan="1">386 (31.3)</td><td align="left" rowspan="1" colspan="1">448 (36.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Eastern Europe</td><td align="left" rowspan="1" colspan="1">346 (28.0)</td><td align="left" rowspan="1" colspan="1">376 (30.4)</td><td align="left" rowspan="1" colspan="1">397 (32.2)</td><td align="left" rowspan="1" colspan="1">370 (30.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian Pacific</td><td align="left" rowspan="1" colspan="1">131 (10.6)</td><td align="left" rowspan="1" colspan="1">111 (9.0)</td><td align="left" rowspan="1" colspan="1">95 (7.7)</td><td align="left" rowspan="1" colspan="1">113 (9.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">161 (13.0)</td><td align="left" rowspan="1" colspan="1">203 (16.4)</td><td align="left" rowspan="1" colspan="1">267 (21.7)</td><td align="left" rowspan="1" colspan="1">275 (22.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">878 (71.0)</td><td align="left" rowspan="1" colspan="1">929 (75.2)</td><td align="left" rowspan="1" colspan="1">935 (75.8)</td><td align="left" rowspan="1" colspan="1">916 (74.2)</td><td align="left" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia</td><td align="left" rowspan="1" colspan="1">840 (68.0)</td><td align="left" rowspan="1" colspan="1">827 (66.9)</td><td align="left" rowspan="1" colspan="1">813 (65.9)</td><td align="left" rowspan="1" colspan="1">755 (61.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">379 (30.7)</td><td align="left" rowspan="1" colspan="1">419 (33.9)</td><td align="left" rowspan="1" colspan="1">456 (37.0)</td><td align="left" rowspan="1" colspan="1">416 (33.7)</td><td align="left" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR &#x0003c;60&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">93 (7.6)</td><td align="left" rowspan="1" colspan="1">131 (10.7)</td><td align="left" rowspan="1" colspan="1">168 (13.9)</td><td align="left" rowspan="1" colspan="1">194 (16.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">History of PAD</td><td align="left" rowspan="1" colspan="1">82 (6.6)</td><td align="left" rowspan="1" colspan="1">120 (9.7)</td><td align="left" rowspan="1" colspan="1">100 (8.1)</td><td align="left" rowspan="1" colspan="1">136 (11.0)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior MI</td><td align="left" rowspan="1" colspan="1">423 (34.2)</td><td align="left" rowspan="1" colspan="1">401 (32.4)</td><td align="left" rowspan="1" colspan="1">368 (29.8)</td><td align="left" rowspan="1" colspan="1">363 (29.4)</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior PCI</td><td align="left" rowspan="1" colspan="1">320 (25.9)</td><td align="left" rowspan="1" colspan="1">304 (24.6)</td><td align="left" rowspan="1" colspan="1">292 (23.7)</td><td align="left" rowspan="1" colspan="1">249 (20.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">Qualifying event</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">STEMI</td><td align="left" rowspan="1" colspan="1">475 (38.4)</td><td align="left" rowspan="1" colspan="1">522 (42.2)</td><td align="left" rowspan="1" colspan="1">576 (46.7)</td><td align="left" rowspan="1" colspan="1">669 (54.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">UA</td><td align="left" rowspan="1" colspan="1">198 (16.0)</td><td align="left" rowspan="1" colspan="1">165 (13.3)</td><td align="left" rowspan="1" colspan="1">129 (10.5)</td><td align="left" rowspan="1" colspan="1">101 (8.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NSTEMI</td><td align="left" rowspan="1" colspan="1">563 (46.0)</td><td align="left" rowspan="1" colspan="1">549 (44.4)</td><td align="left" rowspan="1" colspan="1">528 (42.8)</td><td align="left" rowspan="1" colspan="1">464 (37.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Days from event</td><td align="left" rowspan="1" colspan="1">20 (13, 26)</td><td align="left" rowspan="1" colspan="1">17 (9, 24)</td><td align="left" rowspan="1" colspan="1">12 (5, 21)</td><td align="left" rowspan="1" colspan="1">6 (3, 13)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PCI</td><td align="left" rowspan="1" colspan="1">915 (74.0)</td><td align="left" rowspan="1" colspan="1">918 (74.3)</td><td align="left" rowspan="1" colspan="1">928 (75.3)</td><td align="left" rowspan="1" colspan="1">990 (80.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fibrinolytics</td><td align="left" rowspan="1" colspan="1">113 (9.1)</td><td align="left" rowspan="1" colspan="1">103 (8.3)</td><td align="left" rowspan="1" colspan="1">108 (8.8)</td><td align="left" rowspan="1" colspan="1">117 (9.5)</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">CAD anatomy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.003</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">One&#x02010;vessel</td><td align="left" rowspan="1" colspan="1">505 (48.4)</td><td align="left" rowspan="1" colspan="1">474 (46.3)</td><td align="left" rowspan="1" colspan="1">424 (40.5)</td><td align="left" rowspan="1" colspan="1">445 (41.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Two&#x02010;vessel</td><td align="left" rowspan="1" colspan="1">293 (28.1)</td><td align="left" rowspan="1" colspan="1">300 (29.3)</td><td align="left" rowspan="1" colspan="1">348 (33.3)</td><td align="left" rowspan="1" colspan="1">357 (32.9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Three&#x02010;vessel</td><td align="left" rowspan="1" colspan="1">245 (23.5)</td><td align="left" rowspan="1" colspan="1">249 (24.3)</td><td align="left" rowspan="1" colspan="1">274 (26.2)</td><td align="left" rowspan="1" colspan="1">284 (26.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Medications</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">1205 (97.5)</td><td align="left" rowspan="1" colspan="1">1175 (95.1)</td><td align="left" rowspan="1" colspan="1">1196 (97.0)</td><td align="left" rowspan="1" colspan="1">1199 (97.2)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">P2Y<sub>12</sub> Inhibitor</td><td align="left" rowspan="1" colspan="1">1086 (87.9)</td><td align="left" rowspan="1" colspan="1">1066 (86.2)</td><td align="left" rowspan="1" colspan="1">1090 (88.4)</td><td align="left" rowspan="1" colspan="1">1125 (91.2)</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x003b2;&#x02010;Blocker</td><td align="left" rowspan="1" colspan="1">1059 (85.7)</td><td align="left" rowspan="1" colspan="1">1099 (88.9)</td><td align="left" rowspan="1" colspan="1">1101 (89.3)</td><td align="left" rowspan="1" colspan="1">1086 (88.0)</td><td align="left" rowspan="1" colspan="1">0.075</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACEI or ARB</td><td align="left" rowspan="1" colspan="1">994 (80.4)</td><td align="left" rowspan="1" colspan="1">1049 (84.9)</td><td align="left" rowspan="1" colspan="1">1027 (83.3)</td><td align="left" rowspan="1" colspan="1">1036 (84.0)</td><td align="left" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">1171 (94.7)</td><td align="left" rowspan="1" colspan="1">1160 (93.9)</td><td align="left" rowspan="1" colspan="1">1178 (95.5)</td><td align="left" rowspan="1" colspan="1">1173 (95.1)</td><td align="left" rowspan="1" colspan="1">0.35</td></tr></tbody></table><table-wrap-foot><fn id="jah32535-note-0002"><p>ACEI indicates angiotensin&#x02010;converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate in mL/min per 1.73&#x000a0;m<sup>2</sup>; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non&#x02010;ST&#x02010;elevation MI; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST&#x02010;elevation MI; UA, unstable angina.</p></fn><fn id="jah32535-note-0003"><p>*Continuous variables are presented as medians (interquartile range) and categorical as numbers (percentages).</p></fn></table-wrap-foot></table-wrap><sec id="jah32535-sec-0015"><title>IL&#x02010;6 Concentration and Risk of Cardiovascular Events</title><p>Median IL&#x02010;6 concentrations were significantly higher for patients who subsequently experienced MACE, cardiovascular death or HF, and individual components during long&#x02010;term follow&#x02010;up, compared with patients without an event (Table&#x000a0;<xref rid="jah32535-tbl-0002" ref-type="table-wrap">2</xref>). A stepwise increase in the risk of MACE was seen across quartiles of IL&#x02010;6 (<italic>P</italic> trend&#x0003c;0.0001; Figure&#x000a0;<xref rid="jah32535-fig-0001" ref-type="fig">1</xref>), including the individual components of cardiovascular death (<italic>P</italic> trend &#x0003c;0.0001) and MI (<italic>P</italic> trend=0.016) but not stroke (<italic>P</italic> trend=0.19). Similarly, a stepwise increase in the risk of cardiovascular death or HF (<italic>P</italic> trend &#x0003c;0.0001) and its components was seen with increasing IL&#x02010;6 concentration (Figure&#x000a0;<xref rid="jah32535-fig-0001" ref-type="fig">1</xref>). A landmark analysis demonstrated consistency of these findings when the analysis period was restricted to beyond 30&#x000a0;days following randomization (Figure&#x000a0;<xref rid="jah32535-fig-0002" ref-type="fig">2</xref>).</p><table-wrap id="jah32535-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Median IL&#x02010;6 Concentration by Long&#x02010;Term Cardiovascular End Points</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">End Point</th><th align="left" rowspan="2" valign="top" colspan="1">N (%) N=4939</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Median IL&#x02010;6 Level (IQR), pg/mL</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Without Event</th><th align="left" valign="top" rowspan="1" colspan="1">With Event</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MACE</td><td align="left" rowspan="1" colspan="1">644 (13.0)</td><td align="left" rowspan="1" colspan="1">2.0 (1.1, 3.9)</td><td align="left" rowspan="1" colspan="1">2.4 (1.3, 4.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death or HF</td><td align="left" rowspan="1" colspan="1">342 (6.9)</td><td align="left" rowspan="1" colspan="1">2.0 (1.1, 3.9)</td><td align="left" rowspan="1" colspan="1">2.7 (1.5, 5.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death</td><td align="left" rowspan="1" colspan="1">204 (4.1)</td><td align="left" rowspan="1" colspan="1">2.0 (1.1, 3.9)</td><td align="left" rowspan="1" colspan="1">2.8 (1.5, 5.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1">401 (8.1)</td><td align="left" rowspan="1" colspan="1">2.0 (1.1, 3.9)</td><td align="left" rowspan="1" colspan="1">2.4 (1.3, 4.2)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">117 (2.3)</td><td align="left" rowspan="1" colspan="1">2.0 (1.2, 3.9)</td><td align="left" rowspan="1" colspan="1">2.2 (1.3, 4.3)</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">HF hospitalization</td><td align="left" rowspan="1" colspan="1">182 (3.7)</td><td align="left" rowspan="1" colspan="1">2.0 (1.1, 3.9)</td><td align="left" rowspan="1" colspan="1">2.9 (1.6, 6.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="jah32535-note-0004"><p>HF indicates heart failure; IQR, interquartile range; MACE, major adverse cardiovascular events including cardiovascular death, myocardial infarction, or stroke.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah32535-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Cumulative 3&#x02010;year Kaplan&#x02010;Meier event rates for major cardiovascular end points by <styled-content style="fixed-case">IL</styled-content>&#x02010;6 quartile. <styled-content style="fixed-case">CV</styled-content> indicates cardiovascular; <styled-content style="fixed-case">CVD</styled-content>, cardiovascular death; <styled-content style="fixed-case">HF</styled-content>, heart failure; KM, Kaplan&#x02010;Meier; <styled-content style="fixed-case">MACE</styled-content>, major adverse cardiovascular events; <styled-content style="fixed-case">MI</styled-content>, myocardial infarction.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e005637-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="jah32535-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Kaplan&#x02010;Meier 30&#x02010;day landmark analysis for MACE (A) and for cardiovascular death or HF (B) by <styled-content style="fixed-case">IL</styled-content>&#x02010;6 quartiles. <styled-content style="fixed-case">CV</styled-content> indicates cardiovascular; <styled-content style="fixed-case">HF</styled-content>,&#x000a0;heart failure; <styled-content style="fixed-case">KM</styled-content>, Kaplan&#x02010;Meier; <styled-content style="fixed-case">MACE</styled-content>, major adverse cardiovascular events including cardiovascular death, <styled-content style="fixed-case">MI</styled-content> or stroke; MI, myocardial infarction.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e005637-g002"/></fig><p>After adjusting for baseline characteristics and clinical predictors, there was a 10% higher risk of MACE (adjusted hazard ratio [adj HR] 1.10, 95% CI 1.01&#x02010;1.19), 24% higher risk of coronary heart disease (CHD) death (adj HR 1.24, 95% CI 1.09&#x02010;1.41), and a 22% higher risk of cardiovascular death or HF (adj HR 1.22, 95% CI 1.11&#x02010;1.34) for each SD increase in log&#x02010;transformed IL&#x02010;6. Patients with the highest IL&#x02010;6 concentrations had a 57% higher risk of MACE (adj HR Q4:Q1 1.57, 95% CI 1.22&#x02010;2.03), more than 2&#x02010;fold higher risk of cardiovascular death or HF (adj HR 2.29, 95% CI 1.6&#x02010;3.29) as well as a higher risk of cardiovascular death (adj HR 2.13, 95% CI 1.35&#x02010;3.36), MI (adj HR 1.39, 95% 1.01&#x02010;1.93) and HF (adj HR 3.1, 95% CI 1.81&#x02010;5.33) (Table&#x000a0;<xref rid="jah32535-tbl-0003" ref-type="table-wrap">3</xref>). After further adjustment for established markers (hsCRP, BNP, hsTnI, and lipoprotein&#x02010;associated phospholipase A<sub>2</sub> activity), IL&#x02010;6 remained significantly associated with the risk of MACE (adj HR Q4:Q1 1.43, 95% CI 1.09&#x02010;1.88) and cardiovascular death or HF (adj HR 1.79, 95% CI 1.22&#x02010;2.63) (Figure&#x000a0;<xref rid="jah32535-fig-0003" ref-type="fig">3</xref>). In the subset of patients who had an assessment of left ventricular ejection fraction during their index hospitalization, inclusion of this factor in multivariable models yielded similar results (Table&#x000a0;<xref rid="jah32535-sup-0001" ref-type="supplementary-material">S2</xref>). Directionally consistent results were observed across both the STEMI and non&#x02010;ST&#x02010;elevation ACS populations (Tables <xref rid="jah32535-sup-0001" ref-type="supplementary-material">S3</xref> and <xref rid="jah32535-sup-0001" ref-type="supplementary-material">S4</xref>, Figures <xref rid="jah32535-sup-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah32535-sup-0001" ref-type="supplementary-material">S2</xref>). The magnitude of the relationship between IL&#x02010;6 and cardiovascular outcomes appeared to be stronger in STEMI than in non&#x02010;ST&#x02010;elevation ACS patients (MACE, <italic>P</italic> interaction=0.05; cardiovascular death or HF, <italic>P</italic> interaction=0.001). Overall, the investigational therapy darapladib did not reduce the primary outcome of CHD death, MI, or urgent coronary revascularization for myocardial ischemia (HR 1.0, 95% CI 0.91&#x02010;1.09). Consistent with the overall trial results, IL&#x02010;6 concentration did not identify patients who benefited from darapladib (<italic>P</italic>&#x02010;value for interaction=0.57).</p><table-wrap id="jah32535-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Risk of Cardiovascular Events by IL&#x02010;6 Quartile Concentration After Adjustment for Clinical Factors</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">End Point</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Hazard Ratio (95% Confidence Interval)</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Trend</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Quartile 2 (N=1192)</th><th align="left" valign="top" rowspan="1" colspan="1">Quartile 3 (N=1177)</th><th align="left" valign="top" rowspan="1" colspan="1">Quartile 4 (N=1168)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MACE</td><td align="left" rowspan="1" colspan="1">1.22 (0.96&#x02010;1.55)</td><td align="left" rowspan="1" colspan="1">1.29 (1.01&#x02010;1.65)</td><td align="left" rowspan="1" colspan="1">1.57 (1.22&#x02010;2.03)</td><td align="left" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death/HF</td><td align="left" rowspan="1" colspan="1">1.37 (0.95&#x02010;1.98)</td><td align="left" rowspan="1" colspan="1">1.4 (0.96&#x02010;2.02)</td><td align="left" rowspan="1" colspan="1">2.29 (1.6&#x02010;3.29)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular death</td><td align="left" rowspan="1" colspan="1">1.14 (0.71&#x02010;1.84)</td><td align="left" rowspan="1" colspan="1">1.4 (0.88&#x02010;2.23)</td><td align="left" rowspan="1" colspan="1">2.13 (1.35&#x02010;3.36)</td><td align="left" rowspan="1" colspan="1">0.0009</td></tr><tr><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">1.18 (0.87&#x02010;1.59)</td><td align="left" rowspan="1" colspan="1">1.37 (1.01&#x02010;1.85)</td><td align="left" rowspan="1" colspan="1">1.39 (1.01&#x02010;1.93)</td><td align="left" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">1.17 (0.68&#x02010;2.0)</td><td align="left" rowspan="1" colspan="1">0.92 (0.52&#x02010;1.64)</td><td align="left" rowspan="1" colspan="1">1.51 (0.85&#x02010;2.67)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">HF hosp</td><td align="left" rowspan="1" colspan="1">1.77 (1.02&#x02010;3.07)</td><td align="left" rowspan="1" colspan="1">1.66 (0.95&#x02010;2.9)</td><td align="left" rowspan="1" colspan="1">3.1 (1.81&#x02010;5.33)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn id="jah32535-note-0005"><p>Model adjusted for age, sex, smoking status, body mass index, race (white vs nonwhite), hypertension, diabetes mellitus, peripheral artery disease, estimated glomerular filtration rate &#x0003c;60&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>, hyperlipidemia, prior myocardial infarction, percutaneous coronary intervention, index qualifying event (ST&#x02010;elevation MI vs non&#x02010;ST&#x02010;elevation acute coronary syndrome), days from qualifying event, randomized treatment arm, LDL&#x02010;cholesterol. HF indicates heart failure; hosp, hospitalization; MACE, major adverse cardiovascular events including cardiovascular death, MI, or stroke; MI, myocardial infarction.</p></fn><fn id="jah32535-note-0006"><p>*Quartile 1 as reference group by Cox Proportional Hazard analysis.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah32535-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Association of baseline <styled-content style="fixed-case">IL</styled-content>&#x02010;6 quartile with cardiovascular end points after further adjustment with biomarkers. Adj <styled-content style="fixed-case">HR</styled-content> indicates adjusted hazard ratio; <styled-content style="fixed-case">CV</styled-content>, cardiovascular; <styled-content style="fixed-case">HF</styled-content>, heart failure; <styled-content style="fixed-case">KM</styled-content>, Kaplan&#x02010;Meier; <styled-content style="fixed-case">MACE</styled-content>, major adverse cardiovascular events including cardiovascular death, <styled-content style="fixed-case">MI</styled-content>, or stroke. Model adjusted for age, sex, smoking status, body mass index, race (white vs nonwhite), hypertension, diabetes mellitus, peripheral artery disease, estimated glomerular filtration rate &#x0003c;60&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>, hyperlipidemia, prior myocardial infarction, percutaneous coronary intervention, index qualifying event (<styled-content style="fixed-case">ST</styled-content>&#x02010;elevation <styled-content style="fixed-case">ACS</styled-content> vs non&#x02010;<styled-content style="fixed-case">ST</styled-content> elevation <styled-content style="fixed-case">ACS</styled-content>), days from qualifying event, randomized treatment arm, low&#x02010;density lipoprotein cholesterol, high&#x02010;sensitivity C&#x02010;reactive protrin, lipoprotein&#x02010;related phospholipase A<sub>2</sub>, high&#x02010;sensitivity troponin I, and B&#x02010;type natriuretic peptide.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e005637-g003"/></fig></sec></sec><sec id="jah32535-sec-0016"><title>Discussion</title><p>Our findings from this exploratory analysis within the SOLID&#x02010;TIMI 52 trial demonstrated that in a cohort of patients post&#x02010;ACS, IL&#x02010;6 is associated with increased risk of cardiovascular events, including recurrent MI, HF, and death, independent of traditional clinical risk factors and known biomarkers, such as hsCRP, associated with vascular disease. This heightened risk emerged early after ACS by 30&#x000a0;days and persisted through a median 2.5&#x000a0;years of follow&#x02010;up.</p><sec id="jah32535-sec-0017"><title>IL&#x02010;6 and Cardiovascular Risk</title><p>The baseline median IL&#x02010;6 concentration in our ACS population was 2.01&#x000a0;pg/mL, which can be compared to a value of 1.46 in a relatively healthy cohort of men without established coronary disease.<xref rid="jah32535-bib-0005" ref-type="ref">5</xref> IL&#x02010;6 has been independently linked to endothelial dysfunction and subclinical atherosclerosis after adjustment for baseline hsCRP<xref rid="jah32535-bib-0015" ref-type="ref">15</xref> and has been shown to be an important predictor of vascular events in patients without clinically evident atherosclerosis at baseline.<xref rid="jah32535-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32535-bib-0006" ref-type="ref">6</xref> The Emerging Risk Factors Collaboration meta&#x02010;analysis pooled data from up to 29 cohorts without established coronary artery disease but with risk factors and demonstrated that for each SD increase in log&#x02010;IL&#x02010;6, there is a 25% increased risk for incident CHD including CHD death.<xref rid="jah32535-bib-0016" ref-type="ref">16</xref> We showed in patients with established CHD, after adjusting for additional clinical risk factors and other inflammatory biomarkers, that the risk of CHD death per SD increase in log&#x02010;IL&#x02010;6 was similar.</p><p>Compared to its state during stable progression of subclinical atherosclerosis, the inflammatory cascade is enhanced following ACS.<xref rid="jah32535-bib-0017" ref-type="ref">17</xref> Progressive atherosclerosis involves the recruitment and differentiation of monocytes within the blood vessel wall, developing into lipid&#x02010;laden proinflammatory foam cells.<xref rid="jah32535-bib-0017" ref-type="ref">17</xref> When these cells subsequently undergo cell death, they cause a large necrotic lipid core and release of IL&#x02010;6 and other cytokines, which is implicated in the destruction of its fibrous cap and plaque instability that leads to ACS.<xref rid="jah32535-bib-0017" ref-type="ref">17</xref> In the Fragmin during Instability in Coronary Artery Disease Trial, elevated hsCRP was additive to troponin T levels in its predictive risk of long&#x02010;term mortality in patients with unstable coronary artery disease.<xref rid="jah32535-bib-0018" ref-type="ref">18</xref> Similarly, hsCRP was an independent predictor of poor outcomes post&#x02010;ACS in the TIMI 11A Trial.<xref rid="jah32535-bib-0019" ref-type="ref">19</xref> However, the synthesis of hsCRP is secondary to upstream interleukin cytokine stimulation in the inflammatory process.</p><p>Concurrently elevated IL&#x02010;6, hsCRP, and NT&#x02010;proBNP were found to be independent predictors of 90&#x02010;day death, shock, or heart failure in patients with STEMI in an APEX&#x02010;AMI subgroup analysis.<xref rid="jah32535-bib-0020" ref-type="ref">20</xref> The Fragmin and Fast Revascularization during Instability in Coronary Artery Disease II trial demonstrated an absolute reduction of 5.1% in mortality seen with an early invasive strategy in those with IL&#x02010;6 concentrations greater than 5&#x000a0;ng/L but no detectable benefit in patients with lower concentrations.<xref rid="jah32535-bib-0009" ref-type="ref">9</xref> In the current study, the magnitude of the relationship between IL&#x02010;6 and cardiovascular outcomes appeared to be stronger in STEMI than in non&#x02010;ST&#x02010;elevation ACS patients, which may in part suggest that IL&#x02010;6 reflects the influence of infarct size. However, we demonstrated that these relationships remained significant when index diagnosis, management strategy, and left ventricular ejection fraction were considered in multivariate models. Further, IL&#x02010;6 was prognostic beyond the acute phase of the event and was associated with an increased risk of adverse outcomes through long&#x02010;term follow&#x02010;up. This suggests that IL&#x02010;6 may have additional predictive value downstream from the initial infarct. In post&#x02010;MI patients the inflammatory cascade has been implicated in altering the coronary vasculature in a diffuse way, leading to subsequent plaque instability at nonculprit atherosclerotic lesions and contributing to a risk of reinfarction and poor cardiovascular outcomes.<xref rid="jah32535-bib-0021" ref-type="ref">21</xref>, <xref rid="jah32535-bib-0022" ref-type="ref">22</xref>, <xref rid="jah32535-bib-0023" ref-type="ref">23</xref>
</p><p>Our study also demonstrated that the highest IL&#x02010;6 quartile was associated with more than 2&#x02010;fold increased risk of HF hospitalization compared to the lowest IL&#x02010;6 quartiles. IL&#x02010;6 is an inducer of matrix metalloproteinase expression,<xref rid="jah32535-bib-0024" ref-type="ref">24</xref> a protein family involved in the upregulation of collagen synthesis, resulting in progressive fibrosis and cardiac remodeling known to contribute to the mechanism of heart failure.<xref rid="jah32535-bib-0025" ref-type="ref">25</xref> In addition, with progression of nonculprit atherosclerosis post&#x02010;ACS, an increase in diastolic dysfunction is likely to accompany ongoing multivessel ischemia. Our study demonstrated that despite its association with the risk of HF hospitalization, IL&#x02010;6 concentration was only weakly correlated with BNP. There was no difference in the use of traditional HF therapies across IL&#x02010;6 quartiles, such as &#x003b2;&#x02010;blockers or angiotensin&#x02010;converting enzyme inhibitors or aldosterone receptor blockers, and therefore, results cannot be explained by an imbalance in optimal medical therapy.</p></sec><sec id="jah32535-sec-0018"><title>IL&#x02010;6 as a Possible Therapeutic Target</title><p>Although the hypothesis can only be confirmed through a clinical trial, the findings in the present study support the concept of IL&#x02010;6 as a potential therapeutic target in ACS. Tocilizumab, a humanized anti&#x02010;IL&#x02010;6 receptor antibody, is currently under study. The ENTRACTE trial is analyzing the effects of tocilizumab versus etanercept on the risk of vascular events in patients with rheumatoid arthritis and a history of CHD (ClinicalTrials.gov NCT01331837). In phase 2 testing, tocilizumab reduced CRP and demonstrated a trend toward troponin T reduction in patients with non&#x02010;ST&#x02010;elevation MI,<xref rid="jah32535-bib-0011" ref-type="ref">11</xref> and in a recent community&#x02010;based study in patients with rheumatoid arthritis has been demonstrated to improve endothelial function.<xref rid="jah32535-bib-0026" ref-type="ref">26</xref> Methotrexate, an anti&#x02010;inflammatory therapeutic agent used in inflammatory arthritis and inhibitor of the central IL&#x02010;1/IL&#x02010;6/CRP axis, is currently under study in CIRT (the Cardiovascular Inflammation Reduction Trial), in which patients with type 2 diabetes mellitus or metabolic syndrome and known coronary disease are randomized to low&#x02010;dose methotrexate or placebo and followed for MACE.<xref rid="jah32535-bib-0027" ref-type="ref">27</xref> Last, the recent CANTOS trial (the Canakinumab Anti&#x02010;Inflammatory Thrombosis Outcomes Study) studied cardiovascular outcomes in stable coronary artery disease patients with persistently elevated hsCRP (&#x0003e;2&#x000a0;mg/L) randomized to placebo or canakinumab, an IL&#x02010;1&#x003b2; inhibitor with upstream effects on IL&#x02010;6.<xref rid="jah32535-bib-0012" ref-type="ref">12</xref> Results demonstrated a significant reduction in the risk of cardiovascular events with canakinumab. Prior to this positive trial, however, effective anti&#x02010;inflammatory therapeutics designed to reduce cardiovascular events have remained elusive. To that end, the p38 MAP&#x02010;kinase inhibitor losmapimod did not improve outcomes in patients hospitalized with ACS<xref rid="jah32535-bib-0028" ref-type="ref">28</xref> despite favorable effects on IL&#x02010;6 and hsCRP.<xref rid="jah32535-bib-0028" ref-type="ref">28</xref>, <xref rid="jah32535-bib-0029" ref-type="ref">29</xref> As a result, challenges continue to exist with identifying meaningful surrogate end points during the development of anti&#x02010;inflammatory therapeutics.</p></sec><sec id="jah32535-sec-0019"><title>Limitations</title><p>This study has limitations that warrant consideration. By design, the SOLID&#x02010;TIMI 52 trial enrolled patients throughout the first 30&#x000a0;days post&#x02010;ACS (median 14&#x000a0;days), and it would be expected that IL&#x02010;6 concentration would rise acutely at the time of qualifying event, and may correlate with the size of the infarct. Left ventricular function was not assessed in all patients and therefore could not be adjusted for in all models. However, the observed association between IL&#x02010;6 and cardiovascular risk remained significant after adjustment for time from the index event as well as the type of ACS and other surrogates of infarct size. Further, the observed results persisted when events during the first 30&#x000a0;days after ACS were excluded. Although Mendelian randomization studies suggest a causal role for IL&#x02010;6 in atherogenesis, the value of IL&#x02010;6 as a therapeutic target can only be confirmed through clinical trials of IL&#x02010;6 blockade designed specifically to test the hypothesis. As with any observational analysis, we cannot exclude the possibility of residual confounding. Moreover, cut points employed in the current study will require prospective validation.</p></sec></sec><sec id="jah32535-sec-0020"><title>Conclusions</title><p>In patients after ACS, IL&#x02010;6 concentration is significantly associated with the risk of adverse cardiovascular outcomes independent of established risk predictors and established biomarkers. Ongoing need exists for clinical trials that target inflammation through IL&#x02010;6&#x02013;related pathways, some of which are now under way in patients with a history of stable coronary disease. Further study is warranted in patients with unstable coronary disease patients to mitigate the progression of culprit and nonculprit disease and improve cardiovascular outcomes.</p></sec><sec id="jah32535-sec-0021"><title>Sources of Funding</title><p>The SOLID&#x02010;TIMI 52 trial was supported by a research grant from GlaxoSmithKline. Reagent support was provided by Singulex (IL&#x02010;6) and Abbott Laboratories (hsTnI, BNP).</p></sec><sec id="jah32535-sec-0022"><title>Disclosures</title><p>Dr Morrow reports grants to the TIMI Study Group from Abbott Laboratories, Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GlaxoSmithKline, Merck, Novartis, Roche Diagnostics, and Singulex, and consultant fees from Abbott Laboratories, AstraZeneca, diaDexus, GlaxoSmithKline, Merck, Peloton, Roche Diagnostics, and Verseon. Dr Cannon reports research grants from Amgen, Arisaph, Boehringer&#x02010;Ingelheim, Bristol&#x02010;Myers Squibb, Daiichi Sankyo, Janssen, Merck, and Takeda, and consulting fees from Alnylam, Amgen, Arisaph, AstraZeneca, Boehringer&#x02010;Ingelheim, Bristol&#x02010;Myers Squibb, GlaxoSmithKline, Kowa, Lipimedix, Merck, Pfizer, Regeneron, Sanofi, and Takeda. Dr Jarolim has received research support through his institution from Abbott Laboratories, AstraZeneca, Daiichi&#x02010;Sankyo, Inc, GlaxoSmithKline, Janssen Scientific Affairs, LLC, Merck, Roche Diagnostics Corporation, Takeda Global Research and Development Center, and Waters Technologies Corporation. Dr Lukas is an employee at GlaxoSmithKline. Dr Hochman is principal investigator for the ISCHEMIA trial for which, in addition to support by National Heart, Lung, and Blood Institute, there are in&#x02010;kind donations from Abbott Vascular, Medtronic, Inc, St Jude Medical, Inc, Volcano Corporation, Arbor Pharmaceuticals, AstraZeneca Pharmaceuticals, Merck, Omron Healthcare, Inc, and financial donations from Arbor Pharmaceuticals, LLC and AstraZeneca Pharmaceuticals. Dr Braunwald reports grant support to his institution from GlaxoSmithKline. For work outside the submitted work, Dr Braunwald reports grant support to his institution from Duke University, Merck, AstraZeneca, Novartis, and Daiichi Sankyo; personal fees for consultancies with The Medicines Company and Theravance; personal fees for lectures from Medscape and Menarini International; uncompensated consultancies and lectures from Merck and Novartis. Dr O'Donoghue reports research grants from Amgen, the Medicines Company, AstraZeneca, Eisai, GlaxoSmithKline, Merck, and Janssen. The remaining authors have no disclosures to report.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jah32535-sup-0001"><caption><p>
<bold>Table&#x000a0;S1.</bold> Baseline Characteristics in Biomarker Population of SOLID&#x02010;TIMI 52</p><p>
<bold>Table&#x000a0;S2.</bold> Association of Baseline IL&#x02010;6 Quartile With Cardiovascular End Points After Further Adjustment for Left Ventricular Dysfunction</p><p>
<bold>Table&#x000a0;S3.</bold> Adjusted Risk of Cardiovascular End Points by Baseline IL&#x02010;6 Quartile in NSTE ACS Population Only</p><p>
<bold>Table&#x000a0;S4.</bold> Adjusted Risk of Cardiovascular End Points by Baseline IL&#x02010;6 Quartile in STEMI Population Only</p><p>
<bold>Figure&#x000a0;S1.</bold> Unadjusted 3&#x02010;year Kaplan&#x02010;Meier Event rates of cardiovascular end points by baseline IL&#x02010;6 quartile in NSTE&#x02010;ACS population only.</p><p>
<bold>Figure&#x000a0;S2.</bold> Unadjusted 3&#x02010;year Kaplan&#x02010;Meier event rates of cardiovascular end points by baseline IL&#x02010;6 quartile in STEMI population only.</p></caption><media xlink:href="JAH3-6-e005637-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah32535-bibl-0001"><title>References</title><ref id="jah32535-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32535-cit-0001">
<string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Hansson</surname>
<given-names>GK</given-names>
</string-name>. <article-title>Progress and challenges in translating the biology of atherosclerosis</article-title>. <source>Nature</source>. <year>2011</year>;<volume>473</volume>:<fpage>317</fpage>&#x02013;<lpage>325</lpage>.<pub-id pub-id-type="pmid">21593864</pub-id></mixed-citation></ref><ref id="jah32535-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32535-cit-0002">
<string-name>
<surname>Heinrich</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Castell</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Andus</surname>
<given-names>T</given-names>
</string-name>. <article-title>Interleukin&#x02010;6 and the acute phase response</article-title>. <source>Biochem J</source>. <year>1990</year>;<volume>265</volume>:<fpage>621</fpage>&#x02013;<lpage>636</lpage>.<pub-id pub-id-type="pmid">1689567</pub-id></mixed-citation></ref><ref id="jah32535-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32535-cit-0003">
<string-name>
<surname>Yudkin</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kumari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Humphries</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Mohamed&#x02010;Ali</surname>
<given-names>V</given-names>
</string-name>. <article-title>Inflammation, obesity, stress and coronary heart disease: is interleukin&#x02010;6 the link?</article-title>
<source>Atherosclerosis</source>. <year>2000</year>;<volume>148</volume>:<fpage>209</fpage>&#x02013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">10657556</pub-id></mixed-citation></ref><ref id="jah32535-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32535-cit-0004">
<string-name>
<surname>Schieffer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Selle</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hilfiker</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hilfiker&#x02010;Kleiner</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Grote</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tietge</surname>
<given-names>UJ</given-names>
</string-name>, <string-name>
<surname>Trautwein</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Luchtefeld</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schmittkamp</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Heeneman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Daemen</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Drexler</surname>
<given-names>H</given-names>
</string-name>. <article-title>Impact of interleukin&#x02010;6 on plaque development and morphology in experimental atherosclerosis</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>:<fpage>3493</fpage>&#x02013;<lpage>3500</lpage>.<pub-id pub-id-type="pmid">15557373</pub-id></mixed-citation></ref><ref id="jah32535-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32535-cit-0005">
<string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Rifai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Stampfer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hennekens</surname>
<given-names>C</given-names>
</string-name>. <article-title>Plasma concentration of interleukin&#x02010;6 and the risk of future myocardial infarction among apparently healthy men</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>101</volume>:<fpage>1767</fpage>&#x02013;<lpage>1772</lpage>.<pub-id pub-id-type="pmid">10769275</pub-id></mixed-citation></ref><ref id="jah32535-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32535-cit-0006">
<string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Hennekens</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Buring</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Rifai</surname>
<given-names>N</given-names>
</string-name>. <article-title>C&#x02010;reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>342</volume>:<fpage>836</fpage>&#x02013;<lpage>843</lpage>.<pub-id pub-id-type="pmid">10733371</pub-id></mixed-citation></ref><ref id="jah32535-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32535-cit-0007">
<string-name>
<surname>Maier</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Altwegg</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Corti</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gay</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hersberger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maly</surname>
<given-names>FE</given-names>
</string-name>, <string-name>
<surname>Sutsch</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Roffi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Neidhart</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eberli</surname>
<given-names>FR</given-names>
</string-name>, <string-name>
<surname>Tanner</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Gobbi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>von Eckardstein</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Luscher</surname>
<given-names>TF</given-names>
</string-name>. <article-title>Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin&#x02010;6 and serum amyloid A but decreased C&#x02010;reactive protein</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>111</volume>:<fpage>1355</fpage>&#x02013;<lpage>1361</lpage>.<pub-id pub-id-type="pmid">15753219</pub-id></mixed-citation></ref><ref id="jah32535-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32535-cit-0008">
<string-name>
<surname>Ammirati</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cannistraci</surname>
<given-names>CV</given-names>
</string-name>, <string-name>
<surname>Cristell</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Vecchio</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Palini</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Tornavall</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Paganoni</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Miendlarzewska</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Sangalli</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Monello</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pernow</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bjornstedt Bennermo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Marenzi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Uren</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Cianflone</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ravasi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Manfredi</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Maseri</surname>
<given-names>A</given-names>
</string-name>. <article-title>Identification and predictive value of interleukin&#x02010;6<sup>+</sup> interleukin&#x02010;10<sup>+</sup> and interleukin&#x02010;6<sup>&#x02013;</sup> interleukin&#x02010;10<sup>+</sup> cytokine patterns in ST&#x02010;elevation acute myocardial infarction</article-title>. <source>Circ Res</source>. <year>2012</year>;<volume>111</volume>:<fpage>1336</fpage>&#x02013;<lpage>1348</lpage>.<pub-id pub-id-type="pmid">22931953</pub-id></mixed-citation></ref><ref id="jah32535-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32535-cit-0009">
<string-name>
<surname>Lindmark</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Diderholm</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sigbahn</surname>
<given-names>A</given-names>
</string-name>. <article-title>Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>286</volume>:<fpage>2107</fpage>&#x02013;<lpage>2113</lpage>.<pub-id pub-id-type="pmid">11694151</pub-id></mixed-citation></ref><ref id="jah32535-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32535-cit-0010">
<collab collab-type="authors">IL6R Genetics Consortium and Emerging Risk Factors Collaboration</collab>
. <article-title>Interleukin&#x02010;6 receptor pathways in coronary heart disease: a collaborative meta&#x02010;analysis of 82 studies</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>379</volume>:<fpage>1205</fpage>&#x02013;<lpage>1213</lpage>.<pub-id pub-id-type="pmid">22421339</pub-id></mixed-citation></ref><ref id="jah32535-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32535-cit-0011">
<string-name>
<surname>Kleveland</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Kunszt</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bratlie</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ueland</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Broch</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Holte</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Michelsen</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Bendz</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Amundsen</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Espevik</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Aakhus</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Damas</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Aukrust</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wiseth</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gullestad</surname>
<given-names>L</given-names>
</string-name>. <article-title>Effect of a single dose of the interleukin&#x02010;6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non&#x02010;ST&#x02010;elevation myocardial infarction: a double&#x02010;blind, randomized, placebo&#x02010;controlled phase 2 trial</article-title>. <source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>2406</fpage>&#x02013;<lpage>2413</lpage>.<pub-id pub-id-type="pmid">27161611</pub-id></mixed-citation></ref><ref id="jah32535-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32535-cit-0012">
<string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Everett</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Thuren</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>MacFadyen</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Ballantyne</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nicolau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Koenig</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Kastelein</surname>
<given-names>JJP</given-names>
</string-name>, <string-name>
<surname>Cornel</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Pais</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pella</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Genest</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cifkova</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lorenzatti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Forster</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kobalava</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Vida&#x02010;Simiti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Flather</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shimokawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dellborg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rossi</surname>
<given-names>PRF</given-names>
</string-name>, <string-name>
<surname>Troquay</surname>
<given-names>RPT</given-names>
</string-name>, <string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Glynn</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>CANTOS Trial Group</article-title>. <source>N Engl J Med</source>. <year>2017</year>; doi: <ext-link ext-link-type="doi" xlink:href="10.1056/NEJMoa1707914">10.1056/NEJMoa1707914</ext-link>. [epub ahead of print].</mixed-citation></ref><ref id="jah32535-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32535-cit-0013">
<string-name>
<surname>O'Donoghue</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Serruys</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Hochman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Maggioni</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Cicconetti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lukas</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Tarka</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>. <article-title>Study design and rationale for the Stabilization of pLaques usIng Darapladib&#x02010;Thrombolysis in Myocardial Infarction (SOLID&#x02010;TIMI 52) trial in patients after an acute coronary syndrome</article-title>. <source>Am Heart J</source>. <year>2011</year>;<volume>162</volume>:<fpage>613</fpage>&#x02013;<lpage>619</lpage>.e1.<pub-id pub-id-type="pmid">21982651</pub-id></mixed-citation></ref><ref id="jah32535-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32535-cit-0014">
<string-name>
<surname>O'Donoghue</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Steen</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Lukas</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Tarka</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Hochman</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Maggioni</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Im</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shannon</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>RY</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Crugnale</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Bonaca</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Watson</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>WD</given-names>
</string-name>, <string-name>
<surname>Serruys</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>. <article-title>Effect of darapladib on major coronary events after an acute coronary syndrome</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>312</volume>:<fpage>1006</fpage>.<pub-id pub-id-type="pmid">25173516</pub-id></mixed-citation></ref><ref id="jah32535-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32535-cit-0015">
<string-name>
<surname>Lee</surname>
<given-names>W&#x02010;Y</given-names>
</string-name>, <string-name>
<surname>Allison</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>D&#x02010;J</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>C&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Barrett&#x02010;Connor</surname>
<given-names>E</given-names>
</string-name>. <article-title>Association of interleukin&#x02010;6 and C&#x02010;reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study)</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>:<fpage>99</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">17196470</pub-id></mixed-citation></ref><ref id="jah32535-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32535-cit-0016">
<string-name>
<surname>Kaptoge</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Seshasai</surname>
<given-names>SRK</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Freitag</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Butterworth</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Borglykke</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Di Angelantonio</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gudnason</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Rumley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lowe</surname>
<given-names>GDO</given-names>
</string-name>, <string-name>
<surname>J&#x000f8;rgensen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Danesh</surname>
<given-names>J</given-names>
</string-name>. <article-title>Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta&#x02010;analysis</article-title>. <source>Eur Heart J</source>. <year>2014</year>;<volume>35</volume>:<fpage>578</fpage>&#x02013;<lpage>589</lpage>.<pub-id pub-id-type="pmid">24026779</pub-id></mixed-citation></ref><ref id="jah32535-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32535-cit-0017">
<string-name>
<surname>Swirski</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Nahrendorf</surname>
<given-names>M</given-names>
</string-name>. <article-title>Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure</article-title>. <source>Science</source>. <year>2013</year>;<volume>339</volume>:<fpage>161</fpage>&#x02013;<lpage>166</lpage>.<pub-id pub-id-type="pmid">23307733</pub-id></mixed-citation></ref><ref id="jah32535-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32535-cit-0018">
<string-name>
<surname>Lindahl</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Toss</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Siegbahn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Venge</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>. <article-title>Markers of myocardial damage and inflammation in relation to long&#x02010;term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>343</volume>:<fpage>1139</fpage>&#x02013;<lpage>1147</lpage>.<pub-id pub-id-type="pmid">11036119</pub-id></mixed-citation></ref><ref id="jah32535-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32535-cit-0019">
<string-name>
<surname>Morrow</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Rifai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Antman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Weiner</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>McCabe</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>. <article-title>C&#x02010;reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>1998</year>;<volume>7</volume>:<fpage>1460</fpage>&#x02013;<lpage>1465</lpage>.</mixed-citation></ref><ref id="jah32535-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32535-cit-0020">
<string-name>
<surname>Van Diepen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Lopes</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Stebbins</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hasselblad</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Ezekowitz</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Reist</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Hochman</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Theroux</surname>
<given-names>P</given-names>
</string-name>. <article-title>Prognostic relevance of baseline pro&#x02010; and anti&#x02010;inflammatory markers in STEMI: an APEX AMI substudy</article-title>. <source>Int J Cardiol</source>. <year>2013</year>;<volume>168</volume>:<fpage>2127</fpage>&#x02013;<lpage>2133</lpage>.<pub-id pub-id-type="pmid">23394896</pub-id></mixed-citation></ref><ref id="jah32535-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32535-cit-0021">
<string-name>
<surname>Dutta</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Courties</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Leuschner</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gorbatov</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Robbins</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Iwamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Heidt</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Majmudar</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Lasitschka</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Etzrodt</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Waterman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Waring</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Chicoine</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>van der Laan</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Niessen</surname>
<given-names>HWM</given-names>
</string-name>, <string-name>
<surname>Piek</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Rubin</surname>
<given-names>BB</given-names>
</string-name>, <string-name>
<surname>Butany</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stone</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Morrow</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Vinegoni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Moskowitz</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Pittet</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Swirski</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Weissleder</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nahrendorf</surname>
<given-names>M</given-names>
</string-name>. <article-title>Myocardial infarction accelerates atherosclerosis</article-title>. <source>Nature</source>. <year>2012</year>;<volume>487</volume>:<fpage>325</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">22763456</pub-id></mixed-citation></ref><ref id="jah32535-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32535-cit-0022">
<string-name>
<surname>Goldstein</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Demetriou</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Grines</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Pica</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shoukfeh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>O'Neill</surname>
<given-names>WW</given-names>
</string-name>. <article-title>Multiple complex coronary plaques in patients with acute myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>343</volume>:<fpage>915</fpage>&#x02013;<lpage>922</lpage>.<pub-id pub-id-type="pmid">11006367</pub-id></mixed-citation></ref><ref id="jah32535-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32535-cit-0023">
<string-name>
<surname>Stone</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Maehara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lansky</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>de Bruyne</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cristea</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mintz</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Mehran</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>McPherson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Farhat</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Marso</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Parise</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Templin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Serruys</surname>
<given-names>PW</given-names>
</string-name>; <collab collab-type="authors">PROSPECT Investigators</collab>
. <article-title>A prospective natural&#x02010;history study of coronary atherosclerosis</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>226</fpage>&#x02013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">21247313</pub-id></mixed-citation></ref><ref id="jah32535-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32535-cit-0024">
<string-name>
<surname>Kothari</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pestana</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mesraoua</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Elchaki</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Dannenberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Falcone</surname>
<given-names>D</given-names>
</string-name>. <article-title>IL&#x02010;6&#x02010;mediated induction of matrix metalloproteinase&#x02010;9 is modulated by JAK&#x02010;dependent IL&#x02010;10 expression in macrophages</article-title>. <source>J. Immunol</source>. <year>2014</year>;<volume>192</volume>:<fpage>349</fpage>&#x02013;<lpage>357</lpage>.<pub-id pub-id-type="pmid">24285838</pub-id></mixed-citation></ref><ref id="jah32535-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32535-cit-0025">
<string-name>
<surname>Polyakova</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Loeffler</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hein</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Miyagawa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Piotrowska</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Dammer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Risteli</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schaper</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kostin</surname>
<given-names>S</given-names>
</string-name>. <article-title>Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles</article-title>. <source>Int J Cardiol</source>. <year>2011</year>;<volume>151</volume>:<fpage>18</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">20546954</pub-id></mixed-citation></ref><ref id="jah32535-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32535-cit-0026">
<string-name>
<surname>Bacchiega</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Bacchiega</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Gomez Usnayo</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bedirian</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>da Rocha Castelar Pinheiro</surname>
<given-names>G</given-names>
</string-name>. <article-title>Interleukin 6 inhibition and coronary artery disease in a high&#x02010;risk population: a prospective community&#x02010;based clinical study</article-title>. <source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<fpage>e005038</fpage> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.116.005038">10.1161/JAHA.116.005038</ext-link>.<pub-id pub-id-type="pmid">28288972</pub-id></mixed-citation></ref><ref id="jah32535-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32535-cit-0027">
<string-name>
<surname>Everett</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Pradhan</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Paynter</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Macfadyen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zaharris</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Clearfield</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hasan</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Glynn</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Rationale and Design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis</article-title>. <source>Am Heart J</source>. <year>2013</year>;<volume>166</volume>:<fpage>199</fpage>&#x02013;<lpage>207</lpage>.e15.<pub-id pub-id-type="pmid">23895801</pub-id></mixed-citation></ref><ref id="jah32535-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah32535-cit-0028">
<string-name>
<surname>O'Donoghue</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Glaser</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cavender</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Aylward</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Bonaca</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Budaj</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>RY</given-names>
</string-name>, <string-name>
<surname>Dellborg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kiss</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Kovar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kuder</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Im</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Lepore</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Lopez&#x02010;Sendon</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Ophuis</surname>
<given-names>TO</given-names>
</string-name>, <string-name>
<surname>Parkhomenko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shannon</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Spinar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tanguay</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Ruda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Theroux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Laws</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Morrow</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>:<fpage>1591</fpage>&#x02013;<lpage>1599</lpage>.<pub-id pub-id-type="pmid">27043082</pub-id></mixed-citation></ref><ref id="jah32535-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah32535-cit-0029">
<string-name>
<surname>Melloni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sprecher</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Sarov&#x02010;Blat</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Heitner</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Aylward</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tanguay</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>DeWinter</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Marber</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Lerman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hasselblad</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>. <article-title>The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale</article-title>. <source>Am Heart J</source>. <year>2012</year>;<volume>164</volume>:<fpage>646</fpage>&#x02013;<lpage>653</lpage>.<pub-id pub-id-type="pmid">23137494</pub-id></mixed-citation></ref></ref-list></back></article>